Intelgenx Technologies Corp. (IGXT) Stock Price, News, Quotes-Moomoo

Account Info

Log Out

US Stock MarketDetailed Quotes

IGXT Intelgenx Technologies Corp.

Watchlist

0.167000
0.0000000.00%

15min DelayTrading Aug 9 16:00 ET

29.17MMarket Cap-2783P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Express News | Intelgenx Provides Update on Previously Announced Sale and Investment Solicitation Process
ReutersJul 19 16:05 ET
Express News | Intelgenx Obtains Preliminary Efficacy Results for the ‘Buena’ Montelukast Versafilm® Phase 2a Clinical Trial in Patients With Mild to Moderate Alzheimer’s Disease
ReutersJul 3 08:00 ET
IntelGenx Announces Initiation of the Sale and Investment Solicitation Process
GlobeNewswireJun 11 08:52 ET
IntelGenx Begins Restructuring Proceedings Under CCAA to Implement Review of Strategic Alternatives
MT NewswiresMay 21 06:44 ET
IntelGenx Initiates Restructuring Proceedings Under the CCAA to Implement a Review of Its Strategic Alternatives
Yahoo FinanceMay 17 10:04 ET
Intelgenx Technologies Corp. | 10-Q: Q1 2024 Earnings Report
SECMay 15 16:28 ET · Announcements

Comments

BioPharm Insight US

Apr 24, 2023 11:52

Columns Weekly FDA Drug Pipeline Calendar (April 24 - April 28)

Hello mooers, welcome to another week of the FDA calendar. Here are what happened last week and what's coming up this week.
BIGGEST MOVERS FROM THIS WEEK
The CEO of $CNS Pharmaceuticals (CNSP.US)$ has disclosed the acquisition of 15,000 shares at a mean price of $0.69 per share. Shares closed the week down 20% at $1.89.
$Dermata Therapeutics (DRMA.US)$ received FDA approval for its proposed protocols and regulations for the Phase 3 clin...

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall

No Data

IGXT Intelgenx Technologies Corp.

Trade Overview

Capital Trend

News

Comments

Analysis

Analyst Rating

Price Target